KAREN L. SMITH - Corporate Board Profile

SANGAMO THERAPEUTICS, INC

Filing Date	Source Excerpt
2020-04-02	Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M., age 52, has served on our Board of Directors since June 2018. The Compensation Committee consists of three directors: Ms. Parker, Dr. Smith and Mr. Zakrzewski. Dr. Smith received total compensation of $161,937.
2021-04-02	Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M., age 53, has served on our Board of Directors since June 2018. Dr. Smith is a life sciences thought leader with over 20 years of biopharmaceutical experience bringing drugs into the clinic and through commercialization. She has been a key contributor to the successful development of multiple FDA and EMA approved products in several therapeutic areas, including oncology (Herceptin, Vyxeos), rare disease (Defitelio), cardiology (Irbesartan), dermatology (Voluma, Botox), neuroscience (Abilify) and anti-infectives (Teflaro). Since November 2018, Dr. Smith has been providing consulting services internationally. Dr. Smith currently serves as Chief Medical Officer for Emergent BioSolutions, Inc., a public biopharmaceutical company. From May 2019 to January 2020, Dr. Smith served as President and Chief Executive Officer of Medeor Therapeutics, Inc., a biotechnology company. From June 2018 to May 2019, Dr. Smith served as Chief Executive Officer of Eliminate Cancer, Inc. From April 2015 to May 2018, she served as the Global Head of Research & Development and Chief Medical Officer of Jazz Pharmaceuticals plc, a biopharmaceutical company, where she built the R&D function into a pipeline of neuroscience and oncology products across all stages of discovery and development. From 2011 to 2015, she was Senior Vice President, Global Medical Affairs and Global Therapeutic Area Head (Dermatology) for Allergan, Inc., a multi-specialty health care company. Earlier in her career, she held senior leadership roles at AstraZeneca plc and Bristol Myers Squibb Company. Dr. Smith holds several degrees, including an M.D. from the University of Warwick, a Ph.D. in oncology from the University of Western Australia, an M.B.A. from the University of New England and an L.L.M. (Masters in Law) from the University of Salford. Dr. Smith currently serves on the board of directors of Acceleron Pharma, Inc., a public biopharmaceutical company, and Antares Pharma, Inc., a public pharmaceutical company. Dr. Smith previously served on the board of directors of Sucampo Pharmaceuticals, Inc. from July 2017 to February 2018, and Forward Pharma A/S, from June 2016 to June 2017, and serves as the chair of the Strategic Advisory Board of Emyria Limited, a healthcare technology and services company. The Nominating and Corporate Governance Committee and the Board believe that Dr. Smith’s extensive executive experience in global research and development, combined with tenure on prior public company boards provides us with access to a valuable skill-set as we translate our science into genomic medicines using our platform technologies in gene editing, gene therapy, gene regulation and cell therapy. In addition, the Nominating and Corporate Governance Committee and the Board do not believe that Dr. Smith’s outside boards or other commitments limit her ability to devote sufficient time and attention to her duties as a director of Sangamo, particularly given her exemplary attendance record at meetings of the Board and of the Compensation Committee. The Compensation Committee consists of three directors: Mr. Meyers, Dr. Smith and Mr. Zakrzewski. Mr. Zakrzewski serves as Chair of this committee. Dr. Smith received total compensation of $287,672 in 2020.
2022-04-01	Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M., age 54, has served on our Board of Directors since June 2018. The Compensation Committee consists of three directors: Dr. Hillan, Mr. Meyers and Dr. Smith. Dr. Smith serves as the Chair of this committee. The following table sets forth certain information regarding the compensation of each non-employee director for service as a member of the Board of Directors during 2021. Dr. Smith total compensation was $264,937.